Hypoxic red blood cells for sickle cell anemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a special type of red blood cell transfusion that holds less oxygen. It may help people with sickle cell anemia who already get regular transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child are at least 7 years old
- You have sickle cell anemia (HbSS or HbSβ0 thalassemia) and get regular blood transfusions
- You have had transfusions every 2 to 4 weeks for the past 6 months
- If you take iron chelation medicine, you have been on a stable dose for at least 3 months
- You are not pregnant or planning to become pregnant in the next 14 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene editing treatment for sickle cell disease. It aims to modify your own blood stem cells to produce more fetal hemoglobin, which can reduce pain episodes and other complications.
This trial tests a new gene therapy that edits your own blood stem cells to help them make more fetal hemoglobin, which can prevent sickling and reduce the need for transfusions. It is for people with severe sickle cell disease or beta thalassemia who do not have a matched sibling donor.
This trial tests a single dose of gene therapy (CTX001) to improve outcomes for people with severe sickle cell disease or transfusion-dependent beta-thalassemia. It aims to see how well it works and whether it is safe, especially after a planned stem cell transplant process.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
This study tests whether giving red blood cells matched to your child’s RH (a blood marker) can improve safety and fit for people with sickle cell disease who need regular transfusions. It may help reduce mismatches by using blood units selected to match the child’s blood type more closely.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
Hear when a new Sickle Cell Anemia in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.